Pharmamarketeer

Eton’s conjunctivitis treatment fails to win FDA nod; shares tumble

Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment for conjunctivitis, sending its shares tumbling nearly 20 percent in extended trading.

Medhc-fases-banner
Advertentie(s)